These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25242760)

  • 41. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial.
    Tsujita M; Kosugi T; Goto N; Futamura K; Nishihira M; Okada M; Hiramitsu T; Narumi S; Uchida K; Takeda A; Morozumi K; Maruyama S; Watarai Y
    Nephrol Dial Transplant; 2019 Aug; 34(8):1409-1416. PubMed ID: 30561729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease.
    Padullés-Zamora N; Comas-Sugrañes D; Pineda-Yuste Mdel M; Jódar-Masanés R; Martínez-Castelao A
    Nefrologia; 2012; 32(2):221-7. PubMed ID: 22421952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epoetin in the 'untransfusable' anaemic patient: a retrospective case series and systematic analysis of literature case reports.
    Heh-Foster AM; Naber M; Pai MP; Lesar TS
    Transfus Med; 2014 Aug; 24(4):204-8. PubMed ID: 24697987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of anemia with epoetin in kidney transplant recipients.
    Bren A; Arnol M; Kandus A; Varl J; Oblak M; Lindič J; Pajek J; Knap B; Kovač D; Mlinšek G; Buturović-Ponikvar J
    Ther Apher Dial; 2011 Jun; 15(3):257-60. PubMed ID: 21624072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.
    Al-Otaibi T; Gheith O; Halim MA; Abu Attia H; Mansour H; Said T; Nair P; Balaha M; Nampoory MR
    Exp Clin Transplant; 2014 Jun; 12(3):220-6. PubMed ID: 24907722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation.
    Van Biesen W; Vanholder R; Veys N; Verbeke F; Lameire N
    Transplantation; 2005 Feb; 79(3):367-8. PubMed ID: 15699772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study.
    Gesualdo L; London G; Turner M; Lee C; Macdonald K; Goldsmith D; Covic A; Zaoui P; Combe C; Mann J; Dellanna F; Muenzberg M; Abraham I
    Intern Emerg Med; 2013 Aug; 8(5):389-99. PubMed ID: 21590439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
    Shord SS; Cuellar S
    J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
    Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.